FDA OKs new Covid vaccine, available soon
The CDC recommends the new booster to combat the widely-circulating KP.2 strain
What happened
The Food and Drug Administration approved updated Covid-19 vaccines from Pfizer and Moderna yesterday. The new boosters target the KP.2 strain and related offshoots of the Omicron variant that have been spreading in late summer. The Centers for Disease Control and Prevention recommends the new shot for everyone six months and older.
Who said what
Last year's vaccines, which inoculated against a strain no longer in circulation, "offered moderate protection against getting infected" and a "stronger guard against severe disease," The New York Times said. When the match between virus and vaccine "is very good, as we anticipate it would be with the current circulating strains, you get actual protection from infection for several months," said Dr. Paul Sax at Brigham and Women's Hospital in Boston.
What next?
The updated vaccines should be available in pharmacies and clinics within days, at no cost to most people with health insurance and uninsured children. But "unless you're very concerned about acquiring Covid right now, my recommendation would be to get it in September or October," Dr. William Schaffner at the Vanderbilt University School of Medicine said to The Wall Street Journal. "That will provide the best protection throughout the winter season."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Affordability: Does Trump have an answer?Feature Trump ‘refuses to admit there is a problem’
-
How travel insurance through a credit card worksThe explainer Use a card with built-in coverage to book your next trip
-
‘We owe it to our young people not to lie to them anymore’instant opinion Opinion, comment and editorials of the day
-
Tips for surviving loneliness during the holiday season — with or without peoplethe week recommends Solitude is different from loneliness
-
More women are using more testosterone despite limited researchThe explainer There is no FDA-approved testosterone product for women
-
Covid-19 mRNA vaccines could help fight cancerUnder the radar They boost the immune system
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Food may contribute more to obesity than exerciseUnder the radar The devil's in the diet
